ArticleJournal of translational medicine2010
Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.
Article in Journal of translational medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- [Value of immunohistochemical staining with mutation-specific antibodies in detecting EGFR mutations: a meta-analysis].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2014Pooled it
- Pooled it
- C-MET tyrosine kinase receptor: mechanisms, clinical applications and future perspectives in cancer therapy.Signal transduction and targeted therapy · 2026Review
- Benchmarking large-scale single-cell RNA-seq analysis.bioRxiv : the preprint server for biology · 2025Article
- α‑Fetoprotein‑positive hepatoid adenocarcinoma of the stomach and a new classification: A case report.Oncology letters · 2024Article
- A single cell RNAseq benchmark experiment embedding "controlled" cancer heterogeneity.Scientific data · 2024Article
- Fluorescence Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer.Cancers · 2022Review
- COMMD1, from the Repair of DNA Double Strand Breaks, to a Novel Anti-Cancer Therapeutic Target.Cancers · 2021Article
- Article
- Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer.British journal of cancer · 2020Article
- Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents.International journal of molecular sciences · 2020Article
- Article
- Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients.Journal of thoracic disease · 2019Article
- Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets.Cancers · 2019Article
- Epithelial contribution to the profibrotic stiff microenvironment and myofibroblast population in lung fibrosis.Molecular biology of the cell · 2017Article
- Detection of epidermal growth factor receptor mutations in lung adenocarcinoma cytological specimens by immunocytochemistry.Molecular and clinical oncology · 2017Article
- Molecular insights: Suppression of EGFR and AKT activation by a small molecule in non-small cell lung cancer.Genes & cancer · 2017Article
- Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.Molecular and clinical oncology · 2016Article
- Fluence Rate Differences in Photodynamic Therapy Efficacy and Activation of Epidermal Growth Factor Receptor after Treatment of the Tumor-Involved Murine Thoracic Cavity.International journal of molecular sciences · 2016Article
- [Influence of Immunohistochemistry Scoring Criteria in Detecting EGFR Mutations].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunohistochemistry (IHC) with mutation-specific antibodies may be an ancillary method of detecting EGFR mutations in lung cancer patients.
methodsEGFR mutation status was analyzed by DNA assays, and compared with IHC results in five non-small-cell lung cancer (NSCLC) cell lines and tumor samples from 78 stage IV NSCLC patients.
resultsIHC correctly identified del 19 in the H1650 and PC9 cell lines, L858R in H1975, and wild-type EGFR in H460 and A549, as well as wild-type EGFR in tumor samples from 22 patients. IHC with the mAb against EGFR with del 19 was highly positive for the protein in all 17 patients with a 15-bp (ELREA) deletion in exon 19, whereas in patients with other deletions, IHC was weakly positive in 3 cases and negative in 9 cases. IHC with the mAb against the L858R mutation showed high positivity for the protein in 25/27 (93%) patients with exon 21 EGFR mutations (all with L858R) but did not identify the L861Q mutation in the remaining two patients.
conclusionsIHC with mutation-specific mAbs against EGFR is a promising method for detecting EGFR mutations in NSCLC patients. However these mAbs should be validated with additional studies to clarify their possible role in routine clinical practice for screening EGFR mutations in NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.